Recent corporate moves in EU and global markets

March 23, 2026 at 11:12 UTC

2 min read

Corporate actions in EU markets: smart-TV regulation, food acquisition, biotech rally, buyback news

Key Points

EU broadcasters seek tighter smart TV oversight for big tech
Danone (BNp) expands in complete nutrition with Huel acquisition
Apogee Therapeutics shares climb on positive phase 2 data
KANZHUN launches ¥34.5M share buyback to lift returns

EU broadcasters call for stricter smart TV rules

European broadcasters are pressing for tougher oversight of large technology companies in the smart TV market. Their push is aimed at addressing growing concerns about how big tech platforms operate and are regulated in the rapidly expanding connected television space.

The calls focus on smart TV environments in which major technology companies increasingly control distribution, user interfaces and access to content. Broadcasters argue that stronger regulatory scrutiny is needed to govern these dynamics and their impact on media markets.

Danone moves into complete nutrition with Huel

Danone (BNp) has acquired Huel as it seeks to extend its portfolio in the complete nutrition segment. The deal adds a specialist brand focused on complete nutrition products to Danone’s (BNp) existing food and beverage businesses.

By bringing Huel into its portfolio, Danone is positioning itself more firmly in the growing category of complete nutrition, where products are designed to provide a full range of nutrients in convenient formats. The acquisition reflects Danone’s interest in expanding in this space.

Apogee Therapeutics reports positive trial data

Apogee Therapeutics’ share price has risen following positive phase 2 clinical data for Zumilokibart in atopic dermatitis. The information from the trial has been welcomed by investors, who responded by sending the stock higher.

Zumilokibart is being evaluated in patients with atopic dermatitis, and the company’s latest phase 2 results indicate encouraging performance for the investigational therapy. The market reaction underscores investor attention to pipeline progress in dermatology.

KANZHUN enhances shareholder returns via buyback

KANZHUN has repurchased 34.5 million of its own shares, a move described as boosting shareholder returns. Share buybacks reduce the company’s outstanding share count, which can increase the value of remaining shares.

The ¥34.5 million share buyback signals KANZHUN’s decision to deploy capital toward repurchases as a way of returning value to investors. This action comes amid ongoing focus by listed companies on balancing growth investment with direct shareholder returns.

Key Takeaways

Regulatory scrutiny of big tech in smart TV markets is intensifying as European broadcasters push for more oversight of platform behavior and control.
Danone’s purchase of Huel shows established food groups actively expanding into specialized complete nutrition segments through acquisitions.
Positive phase 2 data for Zumilokibart has highlighted Apogee Therapeutics’ clinical pipeline as a key driver of investor sentiment.
KANZHUN’s ¥34.5 million share buyback illustrates the continued use of repurchases as a tool for enhancing shareholder returns in public markets.